Q2 2011 Earnings Call

August 4, 2011 4:30 pm ET


Carol DeGuzman – IR

Steven Engle – Chairman and CEO

Fred Kurland – VP, Finance and CFO

Alan Solinger – VP, Clinical Immunology


Liana Moussatos – Wedbush Securities

Christopher James – MLV

Ross Sweeney [ph] – RBC Capital Markets



Good day, ladies and gentlemen, and welcome to the XOMA second quarter 2011 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator instructions) As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference, Carol DeGuzman, Senior Director of Investor Relations. Ms. DeGuzman, you may begin.

Carol DeGuzman

Thank you, operator. And good afternoon, everyone. A short while ago, we issued our news release, which included financial results for the quarter ended June 30, 2011 and a general business update. Our quarterly report on Form 10-Q was filed with the Securities and Exchange Commission this afternoon. Each document will be available on the XOMA website at xoma.com. Today’s webcast also can be accessed via our website and will be available for replay until the close of business on November 4, 2011.

Joining me on today’s call is Steven Engle, Chairman and Chief Executive Officer; and Fred Kurland, Vice President and Chief Financial Officer. Also joining us is Dr. Alan Solinger, our Vice President of Clinical Immunology. We wish to remind all listeners that certain statements concerning product, conduct or availability of results of clinical trials, entry into a O52 development partnership or potential licensing and collaboration arrangements or other aspects of product developments or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

If you liked this article you might like

XOMA (XOMA) Weak On High Volume

Xoma Stock Soaring on Q4 Earnings Beat

Xoma Stock Surges in After-Hours Trading on Q4 Results

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million